Clinical trial

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic…

NCT00082537 · Merck Sharp & Dohme LLC, Industry · Completed

Key facts

NCT number NCT00082537
Title MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
Official title A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in Pediatric Patients With Persistent Fever and Neutropenia
Lead sponsor Merck Sharp & Dohme LLC, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Neutropenia, Fever
Intervention type Drug
Interventions caspofungin acetate, Comparator: AmBisome
Enrollment 100
Start date Apr 1, 2004
Primary completion Oct 1, 2006
Completion Oct 1, 2006
First posted May 13, 2004
Last update posted Feb 23, 2017

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies